What is the recommended weaning schedule for Spravato (esketamine) 84 mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

No Established Weaning Schedule for Spravato 84mg

There is no FDA-approved or guideline-recommended weaning schedule for discontinuing Spravato (esketamine) 84mg. The FDA label does not provide specific tapering instructions, and current evidence focuses on initiation and maintenance rather than discontinuation protocols 1.

What the FDA Label States

The Spravato prescribing information addresses missed doses but not systematic discontinuation 1:

  • If treatment sessions are missed without worsening depression, continue the current dosing schedule
  • If depression worsens during missed maintenance doses, consider returning to the previous more frequent schedule (e.g., from weekly back to twice weekly)
  • No guidance exists for intentional discontinuation or tapering

Clinical Approach Based on Available Evidence

When to Consider Discontinuation

Evaluate therapeutic benefit at specific timepoints 1:

  • End of 4-week induction phase for both TRD and MDD with suicidal ideation
  • Ongoing assessment during maintenance to determine continued need

Practical Discontinuation Strategy

Since esketamine is a rapid-acting antidepressant with relatively short half-life and the FDA label lacks tapering guidance, abrupt discontinuation may be reasonable in stable patients, but a cautious approach is warranted:

Gradual frequency reduction approach:

  1. If on weekly dosing (56mg or 84mg), extend interval to every 2 weeks for 2-3 administrations
  2. Monitor closely for depression recurrence using validated scales (MADRS, QIDS)
  3. If stable, extend to every 3 weeks for 1-2 administrations
  4. Then discontinue while maintaining oral antidepressant

Critical monitoring parameters:

  • Depression symptom severity (weekly for first month)
  • Suicidal ideation assessment
  • Functional status
  • Patient-reported outcomes

Important Caveats

Esketamine differs fundamentally from traditional antidepressants 2, 3:

  • It is a fast-acting agent, not subject to typical SSRI/SNRI discontinuation syndromes
  • No evidence of physical dependence or withdrawal syndrome in clinical trials 4, 5
  • Most adverse events (dissociation, dizziness, nausea) occur acutely during administration and resolve within 1.5-2 hours 4, 6

The oral antidepressant must be continued 1:

  • Esketamine is approved only as adjunctive therapy with an oral antidepressant
  • Do not discontinue the oral antidepressant when stopping esketamine
  • If discontinuing the oral antidepressant, follow standard tapering protocols for that medication class

Risk of Relapse

Depression recurrence is the primary concern, not withdrawal symptoms:

  • Approximately one-third of patients with TRD fail to maintain response 3
  • Close monitoring for at least 3 months post-discontinuation is essential
  • Have a plan for rapid reinitiation if symptoms recur

If depression worsens after discontinuation:

  • Restart at the previously effective dose and frequency
  • Do not attempt to "push through" worsening symptoms
  • Earlier intervention prevents full relapse

What This Means Clinically

The absence of a formal weaning protocol reflects esketamine's unique pharmacology—it does not require gradual dose reduction to prevent physiological withdrawal. However, the decision to discontinue should be made collaboratively with careful monitoring, as the underlying treatment-resistant depression remains a chronic condition requiring ongoing management 3.

References

Related Questions

Can you provide comprehensive information on Spravato (esketamine) nasal spray, including its indications, dosing schedule, administration requirements, monitoring parameters, contraindications, and alternative treatment options?
For a 2‑hour Spravato (esketamine) monitoring session, how many units of CPT 99417 and CPT 99215 should be billed?
What are the recently FDA-approved antidepressant medications that show great promise for treatment-resistant depression?
Is an adult patient with a history of opioid dependence, bipolar disorder, ADHD, experiencing nightmares and auditory hallucinations, currently on buprenorphine/naloxone (Suboxone) awaiting extended‑release buprenorphine (Sublocade), aripiprazole, quetiapine, clonidine, atomoxetine, propranolol, prazosin, and tizanidine, eligible for Spravato (esketamine nasal spray)?
For esketamine (Spravato), what factors determine whether to start with a 84 mg dose versus a 56 mg dose?
Is methylergonovine (Methergine) safe to use in patients with prolonged QT syndrome?
What fluid‑retaining effects does methylprednisolone have and how should they be monitored in patients at risk for edema or hypertension?
Which oral antibiotic is appropriate for a patient with a large stye and a new stye on the opposite eye who has not improved after five days of topical Maxitrol (dexamethasone/neomycin/polymyxin B)?
For what indications is propranolol FDA approved?
How effective is low‑dose doxepin compared with zolpidem (Ambien) for treating insomnia characterized by difficulty maintaining sleep after initial sleep onset?
Should a patient presenting with a hypertensive emergency that requires intravenous antihypertensive infusion and continuous arterial blood pressure monitoring be admitted to the intensive care unit or to a regular floor?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.